| Literature DB >> 34667235 |
Zeleke Geto1,2, Feyissa Challa3, Tadesse Lejisa3, Tigist Getahun3, Meron Sileshi3, Bikila Nagasa3, Yosef Tolcha3, Yeabkal Daniel3, Misrak Getnet4, Meseret Derbew Molla5, Maria Degef6, Abebe Bekele4, Daniel Seifu6,7.
Abstract
Non-communicable diseases (NCDs) are increasingly becoming the global cause of premature death encompassing cardiovascular diseases (CVDs), cancer, respiratory diseases and diabetes mellitus. However, cardiometabolic risk factors in the general population, especially among the high-risk groups have rarely been assessed in Ethiopia. The study aimed to assess the prevalence of metabolic syndrome, its components and associated factors among staff in the Ethiopian Public Health Institute (EPHI). An institutional-based cross-section study was conducted from March to June 2018 among EPHI staff members. A total of 450 study participants were involved in the study, and the World Health Organization NCD STEPS survey instrument version 3.1 was used for the assessment. The biochemical parameters were analyzed by using COBAS 6000 analyzer. Statistical package for the social science (SPSS) version 20 was used for data analysis. Both bivariate and multivariate logistic regression analyses were used to identify associated risk factors. p value < 0.05 was considered for statistical significance. The overall prevalence of metabolic syndrome was 27.6% and 16.7% according to IDF and NCEP criteria respectively, with males having greater prevalence than females (35.8% vs 19.4%). Central obesity, low high-density lipoprotein (HDL) and hypertension had a prevalence of 80.2%, 41.3%, and 23.6%, respectively. In multivariate analysis increasing age and having a higher body mass index (25-29.9) were significantly associated with metabolic syndromes. The magnitude of metabolic syndrome was relatively high among public employees. Preventive intervention measures should be designed on the modification of lifestyle, nutrition and physical activities, and early screening for early identification of cardiometabolic risks factors should be practised to reduce the risk of developing cardiovascular diseases.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34667235 PMCID: PMC8526710 DOI: 10.1038/s41598-021-99913-6
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Classification criteria for metabolic syndrome based on IDF and NCEP ATP III.
| Components | IDF criteria | NCEP ATP III criteria |
|---|---|---|
| Components | Central obesity Plus at least any two of the other abnormalities | Any two or more of the following abnormalities |
| Abdominal obesity | Waist circumference ≥ 90 cm for men ≥ 80 cm for women | Waist circumference ≥ 102 cm for men ≥ 88 cm for women |
| Dyslipidaemia | Triglycerides ≥ 150 mg/dl Low HDL ≤ 40 mg/dl for men and ≤ 50 mg/dl for women | Triglycerides ≥ 150 mg/dl Low HDL ≤ 40 mg/dl for men and ≤ 50 mg/dl for women |
| Blood pressure | Systolic blood pressure ≥ 130 mmHg and/or diastolic blood pressure ≥ 85 mmHg or current use of antihypertensive drugs) | Systolic blood pressure ≥ 130 mmHg and/or diastolic blood pressure ≥ 85 mmHg or current use of antihypertensive drugs) |
| Fasting Blood Glucose | Fasting plasma glucose ≥ 100 mg/dl | Fasting plasma glucose ≥ 100 mg/dl |
Socio-demographic characteristics of the study participants stratified by sex, EPHI, Addis Ababa, Ethiopia, 2018 (n = 450).
| Characteristics | Total | Sex | p value | |
|---|---|---|---|---|
| Male n (%) | Female n (%) | |||
| Study participant, n (%) | 450 | 232 (51.6) | 218 (48.4) | |
| Mean age, y (SD) | 36.5 (10) | 38 (10) | 35 (10) | 0.018 |
| 18–28 | 97 (21.6) | 34 (14.7) | 63 (28.9) | 0.006 |
| 29–38 | 186 (41.3) | 107 (46.1) | 79 (36.2) | |
| 39–48 | 96 (21.3) | 52 (22.4) | 44 (20.2) | |
| 49–58 | 55 (12.2) | 29 (12.5) | 26 (11.9) | |
| 59–69 | 16 (3.6) | 10 (4.3) | 6 (2.8) | |
| Never married | 156 (34.7) | 73 (31.5) | 83 (38.1) | < 0.005 |
| Married | 265 (58.9) | 156 (67.2) | 109 (50.0) | |
| Separated/divorced/widowed | 29 (6.4) | 3 (1.3) | 26 (11.9) | |
| Less than primary school | 31 (6.9) | 9 (3.9) | 22 (10.1) | < 0.005 |
| Primary school completed | 48 (10.7) | 21 (9.1) | 27 (12.4) | |
| Secondary school completed | 65 (14.4) | 24 (10.3) | 41 (18.8) | |
| College/university completed | 220 (48.9) | 114 (49.1) | 106 (48.6) | |
| Post graduate degree | 86 (19.1) | 64 (29.6) | 22 (10.1) | |
| Quartile1 | 107 (23.8) | 27 (11.6) | 80 (36.7) | < 0.005 |
| Quartile2 | 117 (26) | 50 (21.6) | 67 (30.7) | |
| Quartile3 | 108 (24) | 72 (31.0) | 36 (16.5) | |
| Quartile4 | 118 (26.2) | 83 (35.8) | 35 (16.1) | |
Quartile 1 = < 1500 Birr, Quartile 2 = 1500–3173-birr, Quartile 3 = 3174–6676-birr Quartile 4 = > 6677 birr.
Prevalence of behavioural clinical and biological characteristics of the study participant, EPHI, Addis Ababa, Ethiopia, 2018 (n = 450).
| Characteristics | N (%) of total | Sex | p value | |
|---|---|---|---|---|
| Male n (%) | Female n (%) | |||
| Never smoke | 405 (90) | 190 (81.9) | 215 (98.6) | < 0.005 |
| Current smoker | 19 (4.2) | 18 (7.8) | 1 (0.5) | |
| Previous smoker | 26 (5.8) | 24 (10.3) | 2 (0.9) | |
| No | 150 (33.3) | 60 (25.9) | 90 (41.3) | 0.001 |
| Yes | 300 (66.7) | 172 (74.1) | 128 (58.7) | |
| Vigorous | 133 (29.6) | 74 (31.9) | 59 (27.1) | 0.365 |
| Moderate | 295 (65.6) | 149 (64.2) | 146 (67.0) | |
| Low | 22 (4.8) | 9 (3.9) | 13 (4.9) | |
| Never chewed | 379 (84.2) | 166 (71.6) | 213 (97.7) | < 0.005 |
| Current chewer | 19 (4.2) | 19 (8.2) | 0 (0) | |
| Previous chewer | 52 (11.6) | 47 (20.3) | 5 (2.3) | |
| ≥ 5 | 2 (0.4) | 1 (0.4) | 1 (0.5) | 0.965 |
| < 5 | 448 (99.6) | 231 (99.6) | 217 (99.6) | |
| Normal | 252 (56) | 128 (55.2) | 124 (56.9) | 0.001 |
| Overweight | 167 (37.1) | 97 (41.8) | 70 (32.1) | |
| Obese | 31 (6.9) | 7 (3.0) | 24 (11.0) | |
| Normal | 344 (76.4) | 172 (74.1) | 172 (78.9) | 0.019 |
| Raised blood pressure | 106 (23.6) | 60 (25.9) | 46 (21.1) | |
| Cholesterol < 200 mg/dl | 323 (71.8) | 158 (68.1) | 165 (75.7) | 0.074 |
| Cholesterol ≥ 200 mg/dl | 127 (28.2) | 74 (31.9) | 53 (24.3) | |
| Triglyceride < 150 mg/dl | 363 (80.7) | 161 (64.4) | 202 (92.7) | < 0.005 |
| Triglyceride ≥ 150 mg/dl | 87 (19.3) | 71 (30.6) | 16 (7.3) | |
| Normal HDL mg/dl | 264 (58.7) | 141 (60.8) | 123 (56.4) | 0.349 |
| Low HDL mg/dl | 186 (41.3) | 91 (39.2) | 95 (43.6) | |
| Normal LDL(< 130) mg/dl | 337 (74.9) | 166 (71.6) | 171 (78.4) | 0.092 |
| High LDL (> 130) mg/dl | 113 (25.1) | 66 (28.4) | 47 (21.6) | |
| Normal | 439 (97.6) | 224 (96.6) | 215 (98.6) | 0.121 |
| Hyperglycemia | 11 (2.4) | 8 (3.4) | 3 (1.4) | |
| Normal | 227 (50.4) | 113 (48.7) | 114 (52.3) | 0.447 |
| Dyslipidemia | 223 (49.6) | 119 (51.3) | 104 (47.7.6) | |
| Normal | 89 (19.8) | 28 (12.1) | 61 (28.0) | < 0.005 |
| Obese | 361 (80.2) | 204 (87.9) | 157 (72.0) | |
| Normal | 307 (68.2) | 197 (84.9) | 110 (50.5) | < 0.005 |
| Obese | 143 (31.8) | 35 (15.1) | 108 (49.5) | |
| Normal | 130 (28.9) | 68 (29.3) | 62 (28.4) | 0.839 |
| Obese | 320 (71.1) | 164 (70.7) | 156 (71.6) | |
*BMI body mass index, raised blood pressure (SBP ≥ 140 and/or DBP ≥ 90 mmHg and/or on medication), hyperglycemia (fasting blood glucose ≥ 126 mg/dl and/or on medication), LDL low-density lipoprotein, HDL high-density lipoprotein, HDL low < 40/50 mg/dl (M/F) CO (central obesity waist circumference IDF ≥ 90/80 cm, NCEP-ATP III ≥ 102/88 cm male/female); WHtR (waist to height ratio), CO ≥ 0.5.
Prevalence of blood pressure, blood glucose, lipid profiles abnormalities and central obesity of study participants at EPHI, Addis Ababa, Ethiopia, 2018 (n = 450).
| Characteristics | High blood pressure, n (%) | Elevated fasting blood glucose, n (%) | Dyslipidemia, n (%) | Centrally obese by IDF, n (%) |
|---|---|---|---|---|
| Male | 60 (25.9) | 8 (3.4) | 119 (51.3) | 204 (87.9) |
| Female | 46 (21.1) | 3 (1.4) | 104 (47.7) | 157 (72) |
| Total | 106 (23.6) | 11 (2.4) | 223 (49.6) | 361 (80.2) |
| 18–28 | 9 (9.3) | 0 (0) | 46 (47.4) | 49 (50.5) |
| 29–38 | 24 (12.9) | 1 (0.5) | 88 (47.3) | 157 (84.4) |
| 39–48 | 39 (40.6) | 3 (3.1) | 58 (60.4) | 89 (92.7) |
| 49–58 | 24 (43.6) | 5 (9.1) | 26 (47.3) | 50 (91.9) |
| 59–69 | 10 (62.5) | 2 (12.5) | 5 (32.2) | 16 (100) |
| Never smoked | 91 (22.5) | 7 (1.7) | 202 (49.9) | 319 (78.8) |
| Current smoker | 5 (26.3) | 3 (15.8) | 6 (31.6) | 18 (94.7) |
| Previous smoker | 10 (38.5) | 1 (3.8) | 15 (57.7) | 24 (92.3) |
| No | 23 (15.3) | 1 (0.7) | 74 (49.3) | 108 (72) |
| Yes | 83 (27.7) | 10 (3.3) | 149 (49.7) | 253 (84.3) |
| Vigorous | 36 (27.1) | 2 (1.5) | 65 (48.9) | 114 (83.7) |
| Moderate | 63 (21.4) | 9 (3.1) | 146 (49.5) | 233 (79) |
| Low | 7 (31.8) | 0 (0) | 12 (54.5) | 14 (63.6) |
| Never chewer | 90 (23.7) | 8 (2.1) | 183 (48.3) | 300 (79.2) |
| Current chewer | 2 (10.5) | 1 (5.3) | 10 (52.6) | 16 (84.2) |
| Previous chewer | 14 (26.9) | 2 (3.8) | 30 (57.7) | 45 (86.5) |
| ≥ 5 | 7 (19.4) | 1 (2.8) | 19 (52.8) | 28 (77.8) |
| 3–5 | 19 (30.2) | 2 (3.2) | 31 (49.2) | 46 (73) |
| < 3 | 80 (22.8) | 8 (2.3) | 173 (49.3) | 287 (81.8) |
| Normal | 46 (18.3) | 4 (1.6) | 104 (41.3) | 173 (68.7) |
| Overweight | 42 (25.1) | 4 (2.4) | 102 (61.1) | 158 (94.6) |
| Obese | 18 (58.1) | 3 (9.7) | 17 (54.8) | 30 (96.8) |
| Normal | 14 (10.8) | 1 (0.8) | 45 (34.6) | 46 (35.4) |
| Obese | 92 (28.8) | 10 (3.1) | 178 (55.6) | 315 (98.4) |
| Normal | NA | 4 (1.2) | 171 (49.7) | 198 (73.9) |
| Hypertensive | NA | 7 (6.6) | 52 (49.1) | 163 (89.6) |
| Normal | 99 (22.6) | NA | 219 (49.9) | 321 (78.9) |
| Hyperglycemia | 7 (63.6) | NA | 4 (36.4) | 40 (93) |
| Normal | 54 (23.8) | 7 (3.1) | NA | 171 (75.30 |
| Dyslipidemia | 52 (23.3) | 4 (1.8) | NA | 190 (85.2) |
| Normal | 19 (21.3) | 1 (1.1 | 33 (37.1) | NA |
| Obese | 163 (45.2) | 10 (2.8) | 190 (52.6) | NA |
HTN hypertension, raised blood pressure (systolic BP ≥ 130 mmHg, diastolic BP ≥ 85 mmHg), DM diabetes mellitus (raised fasting glucose ≥ 100 mg/dl), central obesity (defined by a waist circumference ≥ 94 cm for men and ≥ 80 cm for women), Dyslipidemia (defined by raised triglyceride level ≥ 150 mg/dl and reduced HDL < 40 mg/dl in men and < 50 mg/dl in women). WHtR waist to height ratio (0.5 = normal and ≥ 0.5 obese), BMI body mass index.
Bivariate and multivariate analyses of demographic and clinical risk factors for raised blood pressure, raised blood sugar, dyslipidemia and central obesity of study subjects. EPHI, Ethiopia, Addis Ababa, 2018 (n = 450).
| Characteristics | Raised blood pressure | Raised blood glucose | Dyslipidemia | Central obesity based on IDF | ||||
|---|---|---|---|---|---|---|---|---|
| COR1 (95% CI) | AOR2 (95% CI) | COR1 (95% CI) | AOR2 (95% CI) | COR1 (95% CI) | AOR2 (95% CI) | COR1 (95% CI) | AOR2 (95% CI) | |
| Male | 1.00 | – | 1.00 | – | 1.00 | – | 1.00 | 1.00 |
| Female | 0.77 (0.5–1.20) | – | 0.39 (0.10–1.49) | – | 0.87 (0.6–1.25) | – | 0.35 (0.22–0.58) | 0.07 (0.02–0.2)* |
| 18–28 | 1.00 | 1.00 | – | 1.00 | – | 1.00 | 1.00 | |
| 29–38 | 1.45 (0.65–3.25) | 1.11 (0.48–2.58) | – | 1.0 (0.61–1.63) | – | 5.30 (3.02–9.30) | 2.6 (1.05–6.55) | |
| 39–48 | 6.69 (3.01–14.85) | 4.27 (1.8–10.13)* | – | 1.69 (0.96–3.0) | – | 12.45 (5.24–29.62) | 2.78 (0.68–11.5) | |
| 49–58 | 7.57 (3.18–18.04) | 4.53 (1.77–11.6)* | – | 1.0 (0.51–1.93) | – | 9.8 (3.6–26.7) | 1.17 (0.25–5.46) | |
| 59–69 | 16.3 (4.8–55.34) | 8.62 (2.36–31.5)* | – | 0.50 (0.16–1.56) | – | – | – | |
| Never smoked | 1.00 | – | 1.00 | 1.00 | 1.00 | – | 1.00 | – |
| Current smoker | 1.23 (0.43–3.51) | – | 10.66 (2.51–45) | 10.34 (2.2–48.7)* | 0.46 (0.17–1.24) | – | 4.85 (0.64–36.9) | – |
| Previous smoker | 2.16 (0.95–4.92) | – | 2.27 (0.27–19.2) | 1.74 (0.2–15.42) | 1.37 (0.62–3.06) | – | 3.23 (0.75–13.96) | – |
| No | 1.00 | 1.00 | 1.00 | – | 1.00 | – | 1.00 | – |
| Yes | 0.47 (0.28–0.79) | 1.68 (0.96–2.93) | 5.14 (0.65–40.5) | – | 1.01 (0.68–1.5) | – | 2.09 (1.30–3.36) | – |
| Vigorous | 1.00 | – | 1.00 | – | 1.00 | – | 1.00 | 1.00 |
| Moderate | 0.73 (0.46–1.17) | – | 2.06 (0.44–9.67) | – | 1.03 (0.68–1.54) | – | 0.63 (0.36–1.1) | 0.68 (0.35–1.31) |
| Low | 1.23 (0.47–3.33) | – | 0.00 (0.00) | – | 1.25 (0.51–3.11) | – | 0.29 (0.11–0.79) | 0.21 (0.06–0.77) |
| Never chewer | 1.00 | – | 1.00 | – | 1.00 | – | 1.00 | – |
| Current chewer | 0.38 (0.09–1.67) | – | 2.58 (0.31–21.7) | – | 1.19 (0.47–2.99) | – | 1.4 (0.4–4.94) | – |
| Previous chewer | 1.18 (0.61–2.28) | – | 1.85 (0.38–8.98) | – | 1.46 (0.81–2.62) | – | 1.69 (0.73–3.89) | – |
| ≥ 5 | 1.00 | – | 1.00 | – | 1.00 | – | 1.00 | – |
| 3–5 | 1.8 (0.67–4.79) | – | 1.15 (0.1–13.11) | – | 0.87 (0.38–1.97) | – | 0.77 (0.29–2.02) | – |
| < 3 | 1.22 (0.52–2.9) | – | 0.82 (0.1–6.72) | – | 0.87 (0.44–1.73) | – | 1.28 (0.56–2.94) | – |
| Normal | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Overweight | 1.51 (0.94–2.42) | 0.86 (0.50–1.50) | 1.52 (0.37–6.17) | 1.31 (0.31–5.52) | 2.23 (1.5–3.33) | 1.68 (1.07–2.63)* | 8.01 (3.89–16.5) | 4.87 (2.23–10.6)* |
| Obese | 6.2 (2.84–13.55) | 2.31 (0.95–5.59) | 6.64 (1.41–31.2) | 3.18 (0.57–17.8) | 1.73 (0.82–3.66) | 1.25 (0.57–2.74) | 13.4 (1.84–102) | 9.29 (1.07–80.71)* |
| Normal (< 0.5) | 1.00 | 1.00 | 1.00 | – | 1.00 | 1.00 | 1.00 | 1.00 |
| Obese (≥ 0.5) | 3.34 (1.83–6.12) | 1.66 (0.81–3.40) | 4.16 (0.53–32.8) | – | 2.37 (1.55–3.62) | 1.74 (1.07–2.81)* | 115 (44–298) | 399 (82–1080)* |
| Normal | NA | NA | 1.00 | 1.00 | 1.00 | – | 1.00 | 1.00 |
| Hypertension | NA | NA | 6.10 (1.72–20.9) | 4.8 (1.24–18.62)* | 0.97 (0.63–1.51) | – | 4.43 (1.98–9.91) | 1.94 (0.57–6.55) |
| Normal | 1.00 | 1.00 | NA | NA | 1.00 | – | 1.00 | – |
| Hyperglycemia | 6.01 (1.72–20.95) | 2.20 (0.56–8.61) | NA | NA | 0.57 (0.17–1.99) | – | 2.51 (0.32–19.85) | – |
| Normal | 1.00 | – | 1.00 | – | NA | NA | 1.00 | 1.00 |
| Dyslipidemia | 0.97 (0.63–1.51) | – | 0.57 (0.17–1.99) | – | NA | NA | 1.89 (1.17–3.04) | − 1.04 (0.45–2.4) |
Raised blood pressure (systolic BP ≥ 130 mmHg, diastolic BP ≥ 85 mmHg) DM: diabetes mellitus (raised fasting glucose ≥ 100 mg/dl), central obesity (defined by a waist circumference ≥ 94 cm for men and ≥ 80 cm for women), Dyslipidemia (defined by raised triglyceride level ≥ 150 mg/dl and reduced HDL < 40 mg/dl in men and < 50 mg/dl in women).WHtR (waist to height ratio, COR (crude odds ratio), AOR (adjusted odds ratio).
*Significant during multi logistic analysis.
Figure 1Prevalence of Metabolic Syndrome Based on NCEP ATP III and IDF criteria stratified by Age Group and Sex of Participants EPHI, Addis Ababa, Ethiopia, 2018.
Bivariate and multivariate analyses of risk factor components for metabolic syndrome of study subjects. EPHI, Addis Ababa, Ethiopia, 2018 (n = 450).
| Characteristics | MS-IDF | MS-NCEP ATP IIII | ||
|---|---|---|---|---|
| COR (95% CI) | AOR (95% CI) | COR (95% CI) | AOR (95% CI) | |
| Male | 1.00 | 1.00 | 1.00 | – |
| Female | 0.42 (0.27–0.64) | 0.32 (0.16–0.64)* | 0.66 (0.4–1.09) | – |
| 18–28 | 1.00 | 1.00 | 1.00 | 1.00 |
| 29–38 | 3.05 (1.36–6.81) | 2.1 (0.74–5.95) | 3.78 (1.09–13.0) | 1.24 (0.48–7.6) |
| 39–48 | 9.41 (4.12–21.5) | 5.38 (1.72–16.8)* | 13.6 (3.97–46.4) | 3.84 (0.79–18.8) |
| 49–58 | 7.42 (3.0–18.29) | 4.0 (1.09–14.7)* | 14 (3.88–50.4) | 3.3 (0.6–18.05) |
| 59–69 | 18.5 (5.34–64.3) | 81.2 (9.4–669)* | 18.8 (4.06–86.9) | 15 (1.74–129)* |
| Never smoke | 1.00 | 1.00 | 1.00 | – |
| Current smoker | 1.69 (0.65–4.4) | 1.46 (0.15–14) | 2.55 (0.94–6.97) | – |
| Previous smoker | 2.89 (1.3–6.44) | 0.88 (0.23–3.38) | 2.04 (0.82–5.05) | – |
| No | 1.00 | 1.00 | 1.00 | – |
| Yes | 1.72 (1.08–2.74) | 1.28 (0.62–2.63) | 1.72 (0.97–3.04) | – |
| Vigorous | 1.00 | – | 1.00 | – |
| Moderate | 0.93 (0.59–1.47) | – | 0.84 (0.49–1.44) | – |
| Low | 0.94 (0.34–2.58) | – | 1.34 (0.45–3.98) | – |
| Never Chewed | 1.00 | – | 1.00 | 1.00 |
| Current Chewer | 1.32 (0.49–3.58) | – | 1.51 (0.48–4.7) | 1.41 (0.21–9.3) |
| Previous Chewer | 1.79 (0.98–3.28) | – | 2.08 (1.06–4.08) | 1.66 (0.66–4.58) |
| ≥ 5 | 1.00 | – | – | – |
| < 5 | 0.38 (0.02–6.1) | – | – | – |
| Normal | 1.00 | 1.00 | 1.00 | 1.00 |
| Overweight | 4.0 (2.77–7.0) | 4.67 (2.27–9.6)* | 9.04 (4.65–17.6) | 5.28 (2.12–13.7)* |
| Obese | 5.45 (2.48–11.9) | 2.2 (0.6–8.05) | 11 (4.3–28.1) | 1.75 (0.49–6.21) |
| Normal | 1.00 | 1.00 | 1.00 | 1.00 |
| Hypertensive | 6.05 (3.77–9.7) | 28 (9.46–86.9)* | 3.75 (2.22–6.32) | 4.55 (1.88–11.01)* |
| Normal | 1.00 | 1.00 | 1.00 | 1.00 |
| Hyperglycemia | 28.5 (3.61–225) | 126 (6.7–2374)* | 9.55 (2.72–33.5) | 41.5 (4.75–362.9)* |
| Normal | 1.00 | 1.00 | 1.00 | 1.00 |
| Dyslipidemia | 14.8 (8.12–27) | 210 (52–849)* | 13.9 (6.2–30.8) | 85.5 (21.9–332)* |
| Normal | NA | NA | 1.00 | 1.00 |
| Centrally obese | NA | NA | 7.05 (4.09–12.16 | 9.56 (4.11–22.3)* |
MS-IDF metabolic syndrome based on IDF (waist circumference ≥ 94/80 cm plus any two of the following (1) raised blood pressure ≥ 130/85, (2) raised fasting blood glucose ≥ 100 mg/dl, (3) fasting triglyceride ≥ 150 mg/dl and (4) HDL < 40/50 for male/female. MS-NCEP ATPII metabolic syndrome based on ATP III defined by any three of the following (1) waist circumference ≥ 102/88 male/female; (2) hypertriglyceridemia: serum TG ≥ 150 mg/dl, (3) low HDL-C < 40/50 mg/dl male/female, (4) hypertension: SBP ≥ 130 mmHg or DBP ≥ 85 mmHg and (5) fasting plasma glucose ≥ 110 mg/dl.
*Significant during multi logistic analysis.
Figure 2Summary of combined risk factors by sex of study participant based on ATP III definition, EPHI, Addis Ababa, Ethiopia, 2018 (n = 450).